Ra-223 Improves Outcomes in Prostate Cancer With Bone Metastases
Investigators observe low rates of treatment discontinuation and adverse effects with radium-223 as treatment for castration-resistant prostate cancer and bone metastases.
Outcomes Improve With Darolutamide Vs Enzalutamide or Apalutamide in nmCRPC
Darolutamide produces a lower rate of discontinuation compared with enzalutamide or apalutamide among patients with non-metastatic, castration-resistant prostate cancer.
Iberdomide ± Anti-CD20 Therapy Yields Promising Responses in Relapsed/Refractory Lymphoma
Treatment with ibermodide on its own or with anti-CD20 antibodies was well tolerated and demonstrated encouraging responses among patients with relapsed or refractory lymphoma.
Chemotherapy Plus Endocrine Therapy May Confer Further Cognitive Impairment vs. Endocrine Therapy Alone for Breast Cancer Regardless of Menopausal Status
Pre- and postmenopausal women with breast cancer may experience cognitive impairment with chemotherapy and endocrine therapy, which may return to baseline after 36 months.
Two-Year KEYNOTE-365 Update Continues to Show Promise of Pembrolizumab Plus Abiraterone in mCRPC Naïve to Chemo
Antitumor activity and safety of pembrolizumab plus abiraterone acetate appears to be sustained in chemotherapy-naïve castration-resistant prostate cancer.